



# Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis

09/08/2025 04:58:28

## Main Information

### Primary registry identifying number

LBCTR2020043427

### Protocol number

APD334-302

### MOH registration number

### Study registered at the country of origin

Yes

### Study registered at the country of origin: Specify

### Type of registration

Prospective

### Type of registration: Justify

N/A

### Date of registration in national regulatory agency

04/05/2015

### Primary sponsor

Arena Pharmaceuticals Inc.

### Primary sponsor: Country of origin

United States of America

### Date of registration in primary registry

13/03/2024

### Date of registration in national regulatory agency

04/05/2015

### Public title

Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis

### Acronym

### Scientific title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis

### Acronym

### Brief summary of the study: English

The purpose of this study is to assess the efficacy and safety of Etrasimod on clinical remission in participants with moderately to severely active ulcerative colitis (UC)

### Brief summary of the study: Arabic

على تخفيف الاعراض والالام عند المرضى المشاركين في الدراسة و الذين etrasimod الغرض من هذه الدراسة هو تقييم سلامة و فعالية يعانون من التهاب القولون التقرحي المعتدل إلى الشديد

### Health conditions/problem studied: Specify

Ulcerative Colitis (UC)

### Interventions: Specify

Drug: Etrasimod (APD334) 2mg tablet by mouth, once daily up to 12-Week Induction Treatment Period  
Drug: Placebo tablet by mouth, once daily up to 12-Week Induction Treatment Period

### Key inclusion and exclusion criteria: Inclusion criteria

Subjects must meet ALL of the following inclusion criteria to be eligible for enrollment into the study:

1. Men or women 16 to 80 years of age, inclusive, at the time of assent/consent
  2. Ability to provide written informed consent or assent (parent or legal guardian must provide consent for a subject < 18 years of age who has assented to participate in the study or as required per local regulations) and to be compliant with the schedule of protocol assessments
- Disease-specific inclusion criteria:
3. Diagnosed with UC ≥ 3 months prior to screening. The diagnosis of UC must be confirmed by endoscopic and histologic evidence. The





endoscopy and histology report should be present in the source documents; however, if not available, the screening endoscopy and histology may serve as such

4. Active UC confirmed by endoscopy with  $\geq 10$  cm rectal involvement. Inclusion of subjects with proctitis only at baseline will be capped at 15% of the total subjects enrolled.

5. Moderately to severely active UC defined as MMS of 4 to 9, including an ES of  $\geq 2$  and RB score  $\geq 1$

6. Received a surveillance colonoscopy (performed according to local standard) within 12 months before baseline to rule out dysplasia in subjects with pancolitis  $> 8$  years duration or subjects with left-sided colitis  $> 12$  years duration. Subjects without a surveillance colonoscopy within the prior 12 months will have a colonoscopy at screening (ie, in place of screening proctosigmoidoscopy). Any adenomatous polyps must be removed prior to their first dose of study treatment.

Prior treatment:

7. Demonstrated an inadequate response to, loss of response to, or intolerance to at least 1 of the following therapies as defined below:

Conventional therapy

a. Oral 5-aminosalicylic acid (5-ASA) compounds

b. Corticosteroids

c. Thiopurines

Biologic therapy or JAK inhibitor therapy

a. Antitumor necrosis factor alpha (TNF $\alpha$ ) antibodies (eg, infliximab, adalimumab, golimumab, or biosimilars)

b. Anti-integrin antibodies (eg, vedolizumab)

c. JAK inhibitors (eg, tofacitinib)

Note: The medication used to qualify the subject for entry into this category must be approved for the treatment of UC in the country of use.

Concomitant treatments:

8. Subjects are permitted to be receiving a therapeutic dose of the following drugs:

- Oral 5-ASA compounds provided the dose has been stable for  $\geq 2$  weeks immediately prior to randomization

- Oral corticosteroid therapy (prednisone at a stable dose  $\leq 20$  mg/day, budesonide at a stable dose  $\leq 9$  mg/day, or equivalent steroid) provided the dose has been stable for the 4 weeks immediately prior to the screening endoscopy assessment

- Immunosuppressive agents such as oral azathioprine or 6-mercaptopurine must be discontinued  $\geq 2$  weeks prior to randomization

- Probiotics (eg, Culturelle®, *Saccharomyces boulardii*) provided the dose has been stable for the 2 weeks immediately prior to randomization

- Antidiarrheals (eg, loperamide, diphenoxylate with atropine) for control of chronic diarrhea

If oral aminosaliclates or corticosteroids have been recently discontinued, they must have been stopped for at least 2 weeks prior to the endoscopy used for the baseline MMS.

Other general inclusion criteria:

9. Vital signs at screening and prerandomization taken in the sitting position: heart rate  $\geq 50$  bpm, systolic blood pressure (BP)  $\geq 90$  mm Hg, and diastolic BP  $\geq 55$  mm Hg

10. Screening and pre-randomization 12-lead electrocardiogram (ECG) showing no clinically significant abnormalities with a PR interval  $\leq 200$  ms, Fridericia's corrected QT interval (QTcF)  $< 450$  ms (men) or QTcF  $< 470$  ms (women)

11. Adequate hematological function defined by white blood cell count  $\geq 3.5 \times 10^9/L$  with absolute neutrophil count  $\geq 1.5 \times 10^9/L$ , lymphocyte count  $\geq 0.8 \times 10^9/L$ , platelet count  $\geq 100 \times 10^9/L$ , and hemoglobin  $\geq 8$  g/dL

12. Adequate hepatic function defined by a total bilirubin level  $\leq 1.5 \times$  the upper limit of normal (ULN) range and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels  $\leq 3.0 \times$  ULN. Subjects with an isolated total bilirubin and normal AST and ALT diagnosed with Gilbert's syndrome may participate

13. Adequate renal function defined by an estimated glomerular filtration rate  $\geq 30$  mL/min/1.73 m $^2$  by the CKD-EPI equation at screening

14. Eligible women of childbearing potential must be:

a. Nonpregnant, evidenced by a negative serum beta-human chorionic gonadotropin

( $\beta$ -hCG) pregnancy test at screening and a urine dipstick pregnancy test at Day 1

b. Not breastfeeding

15. Both men and women subjects agree to use a highly effective method of birth control throughout the entire study period, from informed consent through the adverse event reporting period (30 days after the last dose of study treatment), if the possibility of conception exists. Eligible men and women subjects must also agree not to participate in a conception process (ie, actively attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization) during the study and for 30 days after the last dose of study treatment. Highly effective birth control methods include the following:

- Oral, implantable, or injectable contraceptives (starting  $\geq 60$  days before dosing) in combination with a diaphragm with vaginal spermicide, cervical cap with vaginal spermicide, or male condom; hormonal contraceptives (subjects should be consistently taking the hormonal contraceptive for at least 3 months [90 days] prior to screening)

- Standard intrauterine device (IUD; eg, Copper T 380A IUD), intrauterine system (IUS; eg, LNG 20 IUS - progesterone IUD), progesterone implant, or tubal sterilization ( $\geq 180$  days after surgery)

- Vasectomized male subjects using a condom, partner using diaphragm with spermicide, cervical cap with spermicide, estrogen and progesterone oral contraceptives ("the pill"), estrogen and progesterone transdermal patch, vaginal ring, or progesterone injection

- Complete sexual abstinence defined as refraining from heterosexual intercourse for the entire period of risk associated with study treatments. The reliability of sexual



abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the subject. Periodic abstinence (calendar, sympto-thermal, post-ovulation methods) is not acceptable

Note: Women who are surgically sterile or postmenopausal (defined as: 12 consecutive months with no menses without an alternative medical cause) are not considered to be of childbearing potential. If of childbearing potential, female partners of participating male subjects should agree to utilize a highly effective method of contraception for the duration of study participation.

**Key inclusion and exclusion criteria: Gender**

Both

**Key inclusion and exclusion criteria: Specify gender**

**Key inclusion and exclusion criteria: Age minimum**

16

**Key inclusion and exclusion criteria: Age maximum**

80

**Key inclusion and exclusion criteria: Exclusion criteria**

Exclusions related to general health:

1. Severe extensive colitis as evidenced by:

- Physician judgment that the subject is likely to require hospitalization for medical care or surgical intervention of any kind for UC (eg, colectomy) within 12 weeks of baseline
- Current evidence of fulminant colitis, toxic megacolon or recent history (within last 6 months) of toxic megacolon, or bowel perforation
- Previous total or partial colectomy

2. Diagnosis of Crohn's disease or indeterminate colitis or the presence or history of a fistula consistent with Crohn's disease

3. Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis

4. Hospitalization for exacerbation of UC requiring intravenous (IV) steroids within 12 weeks of screening (a single dose of IV steroids given is acceptable)

5. Positive assay or stool culture for pathogens (ova and parasite examination, bacteria) or positive test for Clostridium difficile toxin at screening (If C. difficile is positive, the subject may be treated and retested  $\geq 4$  weeks after completing treatment)

6. Pregnancy, lactation, or a positive serum  $\beta$ -hCG measured during screening

7. Clinically relevant hematologic, hepatic, neurological, pulmonary, ophthalmological, endocrine, metabolic (including, but not limited to, hypo- and hyperkalemia), psychiatric or other major systemic disease making implementation of the protocol or interpretation of the study difficult or would put the subject at risk

8. Recent history (within 2 months of the Screening Visit) of cardiovascular disease, including myocardial infarction or unstable angina

9. Any history of the following, unless treated with an implanted pacemaker or an implanted cardioverter-defibrillator with pacing:

- History or presence of symptomatic bradycardia
- History of sick sinus syndrome or neurocardiogenic syncope
- Second or third-degree atrioventricular (AV) block
- Periods of asystole  $> 3$  seconds

10. Forced expiratory volume at 1 second (FEV1) or forced vital capacity (FVC)  $< 70\%$  of predicted values and FEV1/FVC ratio  $< 0.70$  at screening

11. Uncontrolled diabetes as determined by hemoglobin A1c (HbA1c)  $> 9\%$  at screening, or subjects with diabetes with significant comorbid conditions such as retinopathy

12. History of macular edema or retinopathy

13. Current or past history of active tuberculosis (TB), history of untreated latent TB infection, or test positive for latent TB infection at screening. The following are EXCEPTIONS to this exclusion criteria:

- Subjects with latent TB, who have been ruled out for active TB, have completed an appropriate course of TB prophylaxis treatment per national/local medical guidelines or WHO guidelines, and have not had recent close contact with a person with active TB are eligible to enroll in the study. It is the responsibility of the Investigator to verify the adequacy of previous TB treatment and provide appropriate documentation
- Subjects diagnosed with latent TB at screening, ruled out for active TB and received at least 4 weeks of an appropriate TB prophylaxis regimen may be rescreened for enrollment

Note: The 2 exceptions to this exclusion criterion outlined above do NOT apply to subjects in countries identified by WHO as a high multi-drug resistant TB burden country due to the high risk of latent infection with multi-drug resistance.

14. Known active bacterial, viral, fungal, mycobacterial infection, or other infection (including TB or atypical mycobacterial disease) or any major episode of infection that required hospitalization or treatment with IV antibiotics within 30 days of screening or during screening or oral antibiotics within 14 days prior to screening. Fungal infection of nail beds is allowed

15. Have human immunodeficiency virus (HIV)/acquired immune deficiency syndrome or test positive for HIV antibodies at screening

16. Have acute or chronic hepatitis B infection or test positive for hepatitis B virus (HBV) at screening (positive for hepatitis B surface antigen [HBsAg], or negative for HBsAg and



positive for antihepatitis B core antibody in conjunction with detectable HBV DNA, or detectable HBV DNA)

17. Have current hepatitis C infection or test positive for hepatitis C virus (HCV) at screening as defined by positive for hepatitis C antibody and detectable HCV RNA

18. History of an opportunistic infection (eg, pneumocystis carinii, cryptococcal meningitis, progressive multifocal leukoencephalopathy) or serious bacterial, viral, or fungal infections (eg, disseminated herpes simplex, disseminated herpes zoster) and requiring IV

medication(s) ≤ 3 weeks prior to randomization

19. History of or currently active primary or secondary immunodeficiency

20. History of cancer within the last 5 years, including solid tumors and hematological malignancies (except basal cell and in situ squamous cell carcinomas of the skin that have been excised and resolved) or colonic mucosal dysplasia

21. History of lymphoproliferative disorder, lymphoma, leukemia, myeloproliferative disorder, or multiple myeloma

22. History of alcohol or drug abuse within 1 year prior to randomization

Exclusions related to medications:

23. Prior treatment with sphingosine 1-phosphate receptor modulators

24. Treatment with a biologic agent within 8 weeks or 5 elimination half-lives, whichever is shorter, prior to randomization

25. Treatment with an investigational therapy within 3 months prior to randomization

26. Treatment failure with ≥ 3 biologic agents or ≥ 2 biologics plus a JAK inhibitor approved for treatment of UC

27. Treatment with topical rectal 5-ASA, short-chain fatty acid enemas, or steroids within 2 weeks of screening or during screening

28. Treatment with cyclosporine, tacrolimus, sirolimus, methotrexate, or mycophenolate mofetil within 16 weeks of screening

29. Receipt of a live vaccine within 4 weeks prior to randomization

30. Previous treatment with natalizumab

31. Previous treatment with lymphocyte-depleting therapies (eg, alemtuzumab, anti-CD4, cladribine, rituximab, ocrelizumab, cyclophosphamide, mitoxantrone, total body irradiation, bone marrow transplantation, alemtuzumab, daclizumab)

32. Previous treatment with D-penicillamine, leflunomide, or thalidomide

33. Treatment with IV immune globulin or plasmapheresis within 3 months prior to randomization

34. Chronic use of therapies that moderately/strongly inhibit/induce cytochrome P450 (CYP) 2C8 and 2C9 metabolism and inhibitors of UGT1A7 within 4 weeks prior to randomization

## Type of study

Interventional

## Type of intervention

Pharmaceutical

## Type of intervention: Specify type

N/A

## Trial scope

Therapy

## Trial scope: Specify scope

N/A

## Study design: Allocation

Randomized controlled trial

## Study design: Masking

Blinded (masking used)

## Study design: Control

Placebo

## Study phase

3

## Study design: Purpose

Treatment

## Study design: Specify purpose

N/A

## Study design: Assignment

Parallel

## Study design: Specify assignment

N/A

## IMP has market authorization

No

## IMP has market authorization: Specify

## Name of IMP

APD334 (Etrasimod)

## Year of authorization

## Month of authorization

## Type of IMP



Others

**Pharmaceutical class**

Highly Selective Sphingosine-1 Phosphate (S1P) Receptor Modulator

**Therapeutic indication**

Ulcerative Colitis

**Therapeutic benefit**

Clinical remission of patients with moderately to severely active ulcerative colitis

**Study model**

N/A

**Study model: Explain model**

N/A

**Study model: Specify model**

N/A

**Time perspective**

N/A

**Time perspective: Explain time perspective**

N/A

**Time perspective: Specify perspective**

N/A

**Target follow-up duration**

**Target follow-up duration: Unit**

**Number of groups/cohorts**

**Biospecimen retention**

Samples with DNA\*\*

**Biospecimen description**

Both Samples with DNA and Samples without DNA will be processed

**Target sample size**

16

**Actual enrollment target size**

**Date of first enrollment: Type**

Anticipated

**Date of first enrollment: Date**

01/08/2020

**Date of study closure: Type**

Anticipated

**Date of study closure: Date**

07/02/2024

**Recruitment status**

Complete

**Recruitment status: Specify**

**Date of completion**

07/02/2024

**IPD sharing statement plan**

**IPD sharing statement description**



No

N/A

Additional data URL

Admin comments

Trial status

Approved

## Secondary Identifying Numbers

| Full name of issuing authority    | Secondary identifying number   |
|-----------------------------------|--------------------------------|
| clinicaltrials.gov                | NCT03996369                    |
| European Clinical Trials Database | EudraCT Number: 2018-003986-33 |

## Sources of Monetary or Material Support

| Name                           |
|--------------------------------|
| Arena Pharmaceuticals Inc. USA |

## Secondary Sponsors

| Name |
|------|
| N/A  |

## Contact for Public/Scientific Queries

| Contact type | Contact full name | Address   | Country                     | Telephone         | Email                  | Affiliation              |
|--------------|-------------------|---|-----------------------------|-------------------|------------------------|--------------------------|
| Public       | Hasan Dakkak      | Wahat Al Arab Building<br>3rd floor - Al Arab Street<br>- Barbir - Beirut | Lebanon                     | 009617002<br>7779 | hasan.dakkak@iqvia.com | IQVIA                    |
| Scientific   | Chris Cabell      | 6154 Nancy Ridge Dr. •<br>San Diego, CA 92121                             | United States<br>of America | +1858453<br>7200  | ccabell@arenapharm.com | Arena<br>Pharmaceuticals |



## Centers/Hospitals Involved in the Study

| Center/Hospital name                         | Name of principles investigator | Principles investigator speciality | Ethical approval |
|--|---------------------------------|------------------------------------|------------------|
| American University of Beirut Medical Center | Dr. Alaa Sharara                | Gastroenterology                   | Approved         |
| Hotel Dieu de France Hospital                | Dr. Cesar Yaghi                 | Gastroenterology                   | Approved         |
| Saint George University Medical Center       | Dr. Said Farhar                 | Gastroenterology                   | Approved         |

## Ethics Review

| Ethics approval obtained                        | Approval date | Contact name      | Contact email  | Contact phone |
|---|---------------|-------------------|----------------|---------------|
| Hotel Dieu de France                            | 26/09/2019    | Pr. Sami Richa    | cue@usj.edu.lb | 9611421229    |
| American University of Beirut Medical Center    | 10/09/2020    | Pr. Ali Abou Alfa | N/A            | 9611350000    |
| Saint George Hospital University Medical Center | 24/09/2020    | Dr. Michel Daher  | NA             | 9611441000    |

## Countries of Recruitment

| Name           |
|----------------|
| Australia      |
| Austria        |
| Belgium        |
| Brazil         |
| Bulgaria       |
| Canada         |
| Chile          |
| China          |
| Croatia        |
| Czech Republic |
| Denmark        |
| Estonia        |
|                |



|                          |
|--------------------------|
| France                   |
| Germany                  |
| Hungary                  |
| India                    |
| Italy                    |
| Republic of Korea        |
| Republic of Moldova      |
| Netherlands              |
| Poland                   |
| Portugal                 |
| Russian Federation       |
| Republic of Serbia       |
| Slovakia                 |
| South Africa             |
| Spain                    |
| Taiwan                   |
| Thailand                 |
| Turkey                   |
| Ukraine                  |
| United Kingdom           |
| United States of America |
| Belarus                  |
| Latvia                   |
| Lithuania                |
| Georgia                  |





## Health Conditions or Problems Studied

| Condition          | Code                     | Keyword   |
|--------------------|--------------------------|---|
| Ulcerative Colitis | Ulcerative colitis (K51) | Colitis Colitis, Ulcerative Ulcer Gastroenteritis Gastrointestinal Diseases Digestive System Diseases Colonic Diseases Intestinal Diseases Pathologic Processes Inflammatory Bowel Diseases |

## Interventions

| Intervention | Description                   | Keyword   |
|--------------|-------------------------------|-----------|
| Drug         | APD334 (Etrasimod) 2mg tablet | Etrasimod |
| Drug         | Matching Placebo tablet       | Placebo   |

## Primary Outcomes

| Name   | Time Points | Measure                   |
|--|-------------|---------------------------|
| Proportion of Participants With Clinical Remission | Week 12     | Mayo Component Sub-scores |

## Key Secondary Outcomes

| Name  | Time Points | Measure                   |
|---|-------------|---------------------------|
| Proportion of Participants Achieving Endoscopic Improvement | Week 12     | Mayo Component Sub-scores |
| Proportion of participants With Mucosal Healing             | Week 12     | Geboes Index Scores       |



## Trial Results

Summary results

Study results globally

Date of posting of results summaries

Date of first journal publication of results

Results URL link

Baseline characteristics

Participant flow

Adverse events

Outcome measures

URL to protocol files